newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

  • AEON Biopharma & Daewoong Pharmaceutical signed definitive documents to exchange $15 million in existing convertible notes plus accrued interest.
  • The exchange terms include issuance of new equity, $1.5 million in new notes maturing in 2030, & a cash-exercise warrant for 8 million common shares.
  • If exercised, the warrants could generate over $8 million in additional cash proceeds for AEON.
  • The transaction remains contingent upon approval by AEON's stockholders.
  • Executing the exchange is expected to eliminate more than 90% of AEON's outstanding debt & transform its capital structure.
  • AEON is developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX to seek accelerated U.S. market entry.
  • ABP-450 is manufactured by Daewoong in an FDA-approved facility & is already approved as a biosimilar in India, Mexico, & the Philippines.
  • AEON holds exclusive rights to develop & distribute ABP-450 for therapeutic indications in the U.S., Canada, EU, UK, & other international territories.
  • The company plans to file a proxy statement on Schedule 14A with the SEC to solicit the required stockholder vote.